infliximab

February 24, 2015February 24, 2015

Hospira Launches First Biosimilar Monoclonal Antibody for Adult & Pediatric Crohn’s, Ulcerative Colitis In Europe

News, Ulcerative colitis

Hospira, Inc., a biotechnology company developing biosimilar therapies, has recently announced the launch of Inflectra (infliximab), the first biosimilar monoclonal antibody (mAb), in major European markets. Inflectra is licensed to address several inflammatory conditions such as rheumatoid arthritis, ... Read more

February 23, 2015February 24, 2015

Infliximab in Severe Ulcerative Colitis Delays and Prevents Early Colectomy

News, Ulcerative colitis

According to a study published in the journal Clinical Gastroenterology and Hepatology, the use of infliximab in patients with acute severe ulcerative colitis reduces the need for early colectomy. In the study ... Read more

December 16, 2014December 16, 2014

UK Patients with Moderately to Severely Active UC Gain Access to New Drugs

News, Ulcerative colitis

Patients with moderately to severely active ulcerative colitis, residing in the United Kingdom, now have access to several new drugs thanks to the Final Appraisal Document (FAD) from the National Institute ... Read more

December 3, 2014September 28, 2016

IBD Therapy Infliximab Tested in Pediatric Patients 7 and Under

IBD News, News

A recent study entitled “Infliximab therapy in pediatric patients 7 years of age and younger” reports that infliximab therapy is less efficient in treating inflammatory bowel disease in children aged ... Read more

November 5, 2014November 5, 2014

IBD Drug Entyvio By Takeda Pharmaceuticals Is Not Proved According to IQWiG

News

In an evaluation in accordance with the Act on the Reform of the Market for Medicinal Products (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) recently assessed whether ... Read more

November 3, 2014September 28, 2016

Celltrion Healthcare Presents Clinical Data Showing That Inflammatory Bowel Disease Patients Should Be Treated With Biosimilar Monoclonal Antibody (mAb) Infliximab

IBD News, News

Documented clinical experience was recently presented by Celltrion Healthcare’s satellite symposium during the 2014 United European Gastroenterology (UEGW) showing evidence that patients with inflammatory bowel disease (IBD) — Crohn’s disease and ulcerative colitis — should be treated with the biosimilar monoclonal antibody (mAb) infliximab. ... Read more

October 8, 2014October 8, 2014

IBD Patients Respond Well To Restarting Remicade, According To Study

IBD News, News

A new study entitled “Early Trough Levels and Antibodies to Infliximab Predict Safety and Success of Reinitiation of Infliximab Therapy” published in the journal Clinical Gastroenterology and Hepatology reports the safety and ... Read more

September 15, 2014September 15, 2014

Infliximab Maintains IBD Remission Longer with Dose Adjustment and Monitoring

IBD News, News

It is estimated that roughly 1.4 million Americans suffer from inflammatory bowel diseases (IBDs) such as Crohn’s disease and ulcerative colitis. Every year, over 30,000 new IBD diagnoses are made, ... Read more

September 11, 2014September 11, 2014

Restarting Infliximab Effective After Other Failed IBD Treatments

IBD News, News

Synthetic antibody formulation infliximab may be an effective component of a drug regimen for patients with inflammatory bowel disease (IBD) such as Crohn’s disease and ulcerative colitis. While a number ... Read more